Seuraa 
Viestejä96
Liittynyt5.5.2008

Tein aiheesta melko kattavaa tiedespekulaatiota blogiini (n. 70 tutkimusviitettä).

Valtsun terveysblogi - Fibromyalgian ja CFS:n oireiden taustalla on energia-aineenvaihdunnan häiriö

"Fibromyalgiassa ja siihen liittyvissä sairauksissa keskeisenä piirteenä on elimistön puutteellinen energiantuotanto, minkä voi havaita esimerkiksi solujen puutteellisena ATP-pitoisuutena tai kilpirauhasen vajaatoimintaa vastaavana perusaineenvaihdunnan alenemana. Melko usein taustalla on todettavissa oleva aivolisäkkeen tai kilpirauhasen toimintahäiriö, mutta useimmissa tapauksissa selkeää elimellistä syytä ei kyetä tunnistamaan.

Energiantuotannon parantamiseen keskittyvät hoitomuodot kuten mm. kilpirauhashormonit, CoQ10 ja lähi-infrapuna näyttävät olevan fibromyalgiaan ja vastaaviin sairauksiin selvästi hyödyksi. Myös endotoksemiaa ja tulehdusta hillitsevillä elintapamuutoksilla on mahdollisesti myönteisiä vaikutuksia."

Kommentit (1)

BCK
Seuraa 
Viestejä6960
Liittynyt9.7.2010

Kyseessä voi olla tulehdus aivoissa, ks. alla. Lieneekö se sitten juuri mainitsemassasi aivolisääkkeessäkin (kuuluuko se "keskiaivoihin" eli englanniksi midbrainiin?), en tiedä, mutta sehän sopisi hyvin kuvaan, jos kerran vaikutukset muistuttavat kilpirauhasen vajaatoimintaa.

Lähde:  http://www.scientificamerican.com/article/baffling-chronic-fatigue-syndrome-set-for-diagnostic-overhaul/?WT.mc_id=SA_Facebook

Baffling Chronic Fatigue Syndrome Set for Diagnostic Overhaul

A new study is now providing hope for better understanding—and potentially better diagnosing—the disease. It has revealed a striking pattern of brain inflammation in CFS patients. Meanwhile, diagnosis and definition of the disease could soon be getting a major overhaul as a new $1-million Institute of Medicine (IOM) study gets underway at the request of the U.S. Department of Health and Human Services (HHS). Is the exhausting search for answers about CFS finally coming to an end?

...'The research team found increases in inflammatory markers in regions including the amygdala, thalamus and midbrain in CFS patients who had more severe cognitive troubles. They found more of these markers in thalamus and cingulate cortex in individuals who reported worse pain. And they found higher traces of inflammation in the hippocampus in patients with severe depression.

More than a decade ago, Watanabe's group found tantalizing suggestions that certain neurotransmitters were not being synthesized as well in people with CFS. These patients also had lower levels of serotonin transporters in particular brain areas. Other research had found higher levels of inflammatory cell-signaling proteins called cytokines circulating in the blood. All of these results led Watanabe to look closer for inflammation.

These PET-scan correlations do not precisely explain the symptoms, Watanabe notes. And only a handful of patients were in the study. But the work opens a new trail researchers can follow. Watanabe and his team are now looking into the amount of neuroinflammation in patients with CFS as well as the levels of circulating cytokines, which could both lead to the development of tests for the condition. Having a biologically based test could help those who do have the disease as well as patients who might have a different condition that has similar symptoms, such as depression, fibromyalgia or late-stage Lyme disease, which would be managed differently and potentially be cured with antidepressants, pain relievers or antibiotics. "Most important," Watanabe says, is "how to treat [CFS] patients and how to prevent this disorder." Currently, clinicians can only try to treat the symptoms—not the disease—with medications or lifestyle recommendations. "We are now planning to study therapeutics, such as anti-inflammatory agents, including herbal medicine," which might treat the underlying pathology, Watanabe says.

(Tosin tuossa puhutaan yrttilääkkeistä, joka kyllä herättää vähän epäilyksiä.)

Suosituimmat

Uusimmat

Uusimmat

Suosituimmat